Paclitaxel and Pembrolizumab
About
Membership operator: AND
Therapies: 2
Therapies
Paclitaxel (tx:ncit:C1411)
Pembrolizumab (tx:ncit:C106432)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Paclitaxel, Pembrolizumab | |
| EMA (1) FDA (2) | PD-L1 (CPS) >= 1 | Ovarian Epithelial Tumor | Paclitaxel, Pembrolizumab | |
| EMA (1) FDA (2) | PD-L1 (CPS) >= 1 | High-Grade Serous Fallopian Tube Cancer | Paclitaxel, Pembrolizumab | |
| EMA (1) FDA (2) | PD-L1 (CPS) >= 1 | Peritoneal Serous Carcinoma | Paclitaxel, Pembrolizumab |